TheStreet restated their hold rating on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a report issued on Monday, AnalystRatingsNetwork reports.
“Regeneron Pharmaceuticals (REGN) has been reiterated by TheStreet Ratings as a hold with a ratings score of C+. The company’s strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income and feeble growth in the company’s earnings per share.,” the firm’s analyst commented.
Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) traded down 0.18% during mid-day trading on Monday, hitting $278.99. The stock had a trading volume of 231,128 shares. Regeneron Pharmaceuticals has a 52 week low of $154.16 and a 52 week high of $319.83. The stock has a 50-day moving average of $288.6 and a 200-day moving average of $268.6. The company has a market cap of $27.404 billion and a P/E ratio of 39.79.
Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, November 5th. The company reported $2.40 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.92 by $1.48. The company had revenue of $597.00 million for the quarter, compared to the consensus estimate of $501.93 million. During the same quarter in the prior year, the company posted $1.89 earnings per share. The company’s quarterly revenue was up 39.6% on a year-over-year basis. On average, analysts predict that Regeneron Pharmaceuticals will post $3.83 earnings per share for the current fiscal year.
In other Regeneron Pharmaceuticals news, Director George Sing sold 10,000 shares of the company’s stock on the open market in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $295.00, for a total value of $2,950,000.00. Following the sale, the director now directly owns 112,772 shares in the company, valued at approximately $33,267,740. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
Other equities research analysts have also recently issued reports about the stock. Analysts at Piper Jaffray initiated coverage on shares of Regeneron Pharmaceuticals in a research note to investors on Wednesday, November 27th. They set an overweight rating and a $376.00 price target on the stock. Separately, analysts at Zacks reiterated a neutral rating on shares of Regeneron Pharmaceuticals in a research note to investors on Tuesday, November 26th. They now have a $309.00 price target on the stock. Finally, analysts at Jefferies Group raised their price target on shares of Regeneron Pharmaceuticals from $251.00 to $274.00 in a research note to investors on Wednesday, November 6th. They now have a hold rating on the stock. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have given a buy rating to the stock. The stock has an average rating of Buy and a consensus price target of $280.69.
Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.